Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the...
71 insider purchases on record · latest filing 2025-07-14.
Insiders have also filed 170 sale transactions at COGT.